Aclarion, INC

Aclarion, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of seven directors and the approval of key corporate proposals.

Aclarion, Inc. announced its Board of Directors has authorized a share repurchase program of up to $2.5 million of its outstanding common stock over the next 12 months.

Aclarion, Inc. has adopted a limited duration stockholder rights plan to protect long-term shareholder value and ensure the Board has time for informed decisions.

Aclarion, Inc. announced the closing of a $10.4 million common stock financing, strengthening its balance sheet and extending its cash runway into 2028.

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, expecting to raise approximately $10.36 million for market and product development.

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $2.5 million to fund market and product development, and clinical trials.

Aclarion, Inc. reported a 61.3% revenue increase for the nine months ended September 30, 2025, driven by UK market expansion, while securing over $20 million in capital to extend its operational runway through Q1 2027 despite rising operating losses.

Aclarion, Inc. reported a significant increase in revenue and cash reserves for Q2 2025, driven by UK market expansion, despite widening net losses and increased operating expenses.

Aclarion Inc.'s Q1 2025 shows revenue growth driven by increased patient scans, alongside significant financing activities including public and direct offerings.

Aclarion Inc.'s Q3 2024 results show a decrease in revenue and ongoing losses, alongside efforts to address financial and compliance issues.

Aclarion Inc. reports a net loss of $3.6 million for the first half of 2024, alongside a decrease in revenue and ongoing efforts to address financial challenges.

Aclarion Inc. reported a net loss of $2.4 million for the first quarter of 2024, alongside a decrease in revenue and ongoing concerns about its ability to continue as a going concern.

Aclarion's 2024 10-K filing highlights its ongoing efforts to commercialize its NOCISCAN technology, secure payer contracts, and expand strategic relationships within the low back pain market.

Aclarion, Inc. released its 10-K filing for fiscal year 2023, detailing its financial performance, strategic initiatives, and future outlook in the healthcare technology sector.

Aclarion, Inc. Chief Strategy Officer Ryan Bond was granted 55,000 restricted stock units vesting in June 2027.

Aclarion, Inc. Executive Chairman Jeffrey John Thramann was granted 100,000 restricted stock units vesting in 2027.

Aclarion, Inc. director David K. Neal was granted 20,000 restricted stock units as part of the company's equity incentive plan.

Director Stephen Deitsch was granted 20,000 restricted stock units in Aclarion, Inc. as part of the company's equity incentive plan.

Director Scott Breidbart acquired 5,664 shares of Aclarion, Inc. common stock on the open market.

Director David K. Neal acquired 2,500 shares of Aclarion common stock for $3.10 per share.

Aclarion, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections, ratification of its auditor, and an amendment to its equity incentive plan.

Aclarion, Inc. has adjourned its Annual Meeting of Stockholders to July 21, 2025, to solicit additional votes for the proposals outlined in its definitive proxy statement.

Aclarion, Inc. will hold its 2025 Annual Meeting of Stockholders on July 7, 2025, to vote on director elections, auditor ratification, a reverse stock split proposal, and an equity plan amendment.

Aclarion, Inc. has adjourned its Special Meeting of Stockholders to March 5, 2025, to solicit additional votes regarding proposals outlined in the definitive proxy statement.

Aclarion, Inc. is holding a special meeting of stockholders to approve the issuance of shares related to warrants and to increase the number of authorized shares of common stock.

Aclarion, Inc. is holding its 2024 Annual Meeting of Stockholders on December 31, 2024, to vote on several key proposals, including the election of directors, ratification of auditors, and approval of stock issuances and a reverse stock split.

Aclarion, Inc. has filed a registration statement to offer up to $8.1 million in additional securities, including common stock and warrants.

Aclarion Inc. is set to offer shares of common stock along with Series A and B warrants, and pre-funded warrants in a new public offering.

Aclarion, Inc. details the terms and conditions for a Series A Common Stock Purchase Warrant, including exercise price, termination date, and adjustment mechanisms.

Aclarion, Inc. is seeking to raise capital through a public offering of common stock and warrants, while also addressing ongoing compliance issues with Nasdaq listing requirements.

Aclarion, Inc. has filed an S-1 registration statement for the resale of up to 20 million shares of its common stock by White Lion Capital, while the company addresses compliance issues with Nasdaq listing requirements.

Aclarion, Inc. enters into a warrant agency agreement with VStock Transfer LLC for the issuance, registration, and management of warrants related to a registered offering.

SEG Opportunity Fund, LLC has reported a 9.98% passive ownership stake in Aclarion, Inc., holding 244,043 shares of common stock.

SEG Opportunity Fund, LLC has filed an amended Schedule 13G, indicating zero beneficial ownership of Aclarion, Inc.'s common stock.

SEG Opportunity Fund, LLC has reported a 9.9% beneficial ownership stake in Aclarion Inc., holding 4.4 million shares of common stock.